We were delighted to speak to Dr. Vijay Balasubramanian (UCSF Fresno, Fresno, CA, USA) to learn more around the interim analysis of the EXPEDITE study (ClinicalTrials.gov Identifier: NCT03497689), which investigated whether a short course of parenteral treprostinil therapy would improve tolerability and dosing of oral treprostinil in patients with pulmonary arterial hypertension (PAH).
The abstract ‘Rapid Titration of Parenteral Treprostinil to EXPEDITE Dosing of Oral Treprostinil‘ (Abstract number: P203) was presented at ATS 2022, 13-18 May 2022.
Questions
- What has the EXPEDITE study taught us about the effectiveness of a short course of parenteral treprostinil therapy to improve tolerability and dosing of oral treprostinil in patients with PAH? (0:39)
- What were the aims of the interim analysis? (2:31)
- What different settings and routes of parenteral treprostinil were reported and which were preferred in the interim analysis? (4:34)
- What were your conclusions from the findings of the interim analysis? (6:38)
Disclosures: Vijay Balasubramanian discloses receiving grant/ research support from United Therapeutics and has participated in speaker’s bureaus for Bayer, Janssen, and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
